Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced that its EyeArt AI system for diabetic eye testing has been chosen for deployment in 4 hospitals in Binh Dinh Province, Vietnam. The project is funded by The Fred Hollows Foundation. "We are excited to implement the EyeArt AI system to expand our capabilities in detection and treatment of diabetic retinopathy. It will help us reach our goal to protect the vision of approximately six million people with diabetes living in Vietnam," said Pham Quoc Anh, Vietnam Country Manager for The Fred Hollows Foundation. "This important project will help us continue the work first started by Professor Fred Hollows 29 years ago, fulfilling his vision to bring equitable eye health for all."

Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced that it has successfully fulfilled the contract awarded by Public Health England (PHE) to use Eyenuk's EyeArt AI Eye Screening System to grade 60,000 patient image sets from 6 different National Health Service (NHS) Diabetic Eye Screening Programmes in England. Diabetic retinopathy (DR) is a vision-threatening complication of diabetes and a leading cause of preventable vision loss globally.1 In England, an estimated 4.6 million are living with diabetes, one-third of whom are at risk of developing DR. Diabetes has become a growing health concern as the number of people diagnosed with diabetes in the U.K. has more than doubled in the last 20 years.2 The U.K. has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually),3 as compared with most parts of the world where typically less than half of diabetes patients receive annual eye screening.4 As a result, diabetic retinopathy is no longer the leading cause of blindness in the working age group in England.5

LOS ANGELES--(BUSINESS WIRE)-- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced that it has successfully fulfilled the contract awarded by Public Health England (PHE) to use Eyenuk's EyeArt AI Eye Screening System to grade 60,000 patient image sets from 6 different National Health Service (NHS) Diabetic Eye Screening Programmes in England. Diabetic retinopathy (DR) is a vision-threatening complication of diabetes and a leading cause of preventable vision loss globally.1 In England, an estimated 4.6 million are living with diabetes, one-third of whom are at risk of developing DR. Diabetes has become a growing health concern as the number of people diagnosed with diabetes in the U.K. has more than doubled in the last 20 years.2 The U.K. has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually),3 as compared with most parts of the world where typically less than half of diabetes patients receive annual eye screening.4 As a result, diabetic retinopathy is no longer the leading cause of blindness in the working age group in England.5

LOS ANGELES--(BUSINESS WIRE)--Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced today that the EyeArt AI Eye Screening System was deployed successfully for Italy's first national prevention and diagnosis campaign for retinal and diabetic maculopathy. A total of 2,200 patients were screened at 30 centers across Italy, with more than half chosen for EyeArt AI Eye Screening. The Month of Prevention of Diabetic Retinopathy and Maculopathy was sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society in collaboration with the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk. In Italy, an estimated 3.2 million patients have diabetes. As many as 25% are estimated to be affected by diabetic retinopathy (DR),1 the main cause of vision impairment and blindness among working-age adults.